Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GOSS
Strong SellSinkerGossamer Bio, Inc. · Healthcare · United States · $83M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, and developing immunology, inflammation, and oncology therapies. The company's lead clinical candidate, seralutinib, is an inhaled PDGFR inhibitor being developed for the treatment of pulmonary arterial hypertension (PAH). Gossamer Bio leverages a highly experienced drug development team to target high-value, unmet medical needs within the cardiopulmonary and inflammatory disease spaces.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 114.7M | 48.5M | -57.7% | 53.3M | 35.9M | 20.0M | -35.8% |
| EPS | -0.52 | -0.54 | -0.12 | -0.36 | — | -0.66 | -0.18 | -0.20 | — |
| Shares | 488.8M | 488.8M | 488.8M | 488.8M | 0.0% | 488.8M | — | — | — |
| Debt | 225.7M | 212.5M | 202.9M | 202.9M | -3.5% | 40.1M | — | — | — |
| Equity | 12.1M | 62.8M | 29.5M | -122.8M | 56.3% | — | — | — | — |
| Op CF | -187.0M | -159.2M | -3.5M | -171.3M | — | -162.6M | — | — | — |
| Inv CF | -1.0M | -111.0M | 29.0M | 156.4M | — | — | — | — | — |
| Fin CF | 117.1M | 190.2M | -11.5M | 6.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GOSS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc.(you) | $83M | 2 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| EXOZ | eXoZymes, Inc. | $67M | 2 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%